As a kind of intestinal flora regulator, probiotics show great potential in the treatment of many diseases. However, orally delivered probiotics are often vulnerable to unfriendly gastrointestinal environments, resulting in a low survival rate and decreased therapeutic efficacy. Decorating or encapsulating probiotics with functional biomaterials has become a facile yet useful strategy, and probiotics can be given different functions by wearing different armors. This review systematically discusses the challenges faced by oral probiotics and the research progress of armored probiotics delivery systems. We focus on how various functional armors help probiotics overcome different obstacles and achieve efficient delivery. We also introduce the applications of armor probiotics in disease treatment and analyze the future trends of developing advanced probiotics-based therapies.
{"title":"Armored probiotics for oral delivery.","authors":"Xinyuan Yang, Chong Wang, Qiao Wang, Zhuohao Zhang, Weimin Nie, Luoran Shang","doi":"10.1002/SMMD.20230019","DOIUrl":"10.1002/SMMD.20230019","url":null,"abstract":"<p><p>As a kind of intestinal flora regulator, probiotics show great potential in the treatment of many diseases. However, orally delivered probiotics are often vulnerable to unfriendly gastrointestinal environments, resulting in a low survival rate and decreased therapeutic efficacy. Decorating or encapsulating probiotics with functional biomaterials has become a facile yet useful strategy, and probiotics can be given different functions by wearing different armors. This review systematically discusses the challenges faced by oral probiotics and the research progress of armored probiotics delivery systems. We focus on how various functional armors help probiotics overcome different obstacles and achieve efficient delivery. We also introduce the applications of armor probiotics in disease treatment and analyze the future trends of developing advanced probiotics-based therapies.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":"1 1","pages":"e20230019"},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46004700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-13eCollection Date: 2023-08-01DOI: 10.1002/SMMD.20230013
Xiusen Qin, Mingli Su, Huili Guo, Binying Peng, Rui Luo, Junwen Ye, Hui Wang
Peritoneal surface malignancies (PSM) can originate from tumors in many organs and are highly malignant, and difficult to diagnose and cure, posing a serious threat to the survival of patients. Although the diagnosis and treatment of PSM have made significant progress in the past two decades, numerous challenges remain. Recently, functionalized biomaterials have shown promise for PSM diagnosis and treatment. Hence, we review the progress of functionalized biomaterials for the diagnosis and treatment of PSM. We first introduce the classification and pathogenesis of PSM. We then discuss the applications of functionalized biomaterials for the diagnosis and treatment of PSM. In particular, we focus on functionalized biomaterials as drug carriers for the treatment of PSM, including chemotherapy, immunotherapy, targeted therapy, combination therapy, and other therapies. Finally, we summarized the current challenges and provided a perspective on the diagnosis and treatment of PSM.
{"title":"Functional biomaterials for the diagnosis and treatment of peritoneal surface malignancies.","authors":"Xiusen Qin, Mingli Su, Huili Guo, Binying Peng, Rui Luo, Junwen Ye, Hui Wang","doi":"10.1002/SMMD.20230013","DOIUrl":"10.1002/SMMD.20230013","url":null,"abstract":"<p><p>Peritoneal surface malignancies (PSM) can originate from tumors in many organs and are highly malignant, and difficult to diagnose and cure, posing a serious threat to the survival of patients. Although the diagnosis and treatment of PSM have made significant progress in the past two decades, numerous challenges remain. Recently, functionalized biomaterials have shown promise for PSM diagnosis and treatment. Hence, we review the progress of functionalized biomaterials for the diagnosis and treatment of PSM. We first introduce the classification and pathogenesis of PSM. We then discuss the applications of functionalized biomaterials for the diagnosis and treatment of PSM. In particular, we focus on functionalized biomaterials as drug carriers for the treatment of PSM, including chemotherapy, immunotherapy, targeted therapy, combination therapy, and other therapies. Finally, we summarized the current challenges and provided a perspective on the diagnosis and treatment of PSM.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230013"},"PeriodicalIF":0.0,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43426632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-05eCollection Date: 2023-08-01DOI: 10.1002/SMMD.20230017
Xiang Lin, Lu Fan, Li Wang, Anne M Filppula, Yunru Yu, Hongbo Zhang
The proper organization of cells and tissues is essential for their functionalization in living organisms. To create materials that mimic natural structures, researchers have developed techniques such as patterning, templating, and printing. Although these techniques own several advantages, these processes still involve complexity, are time-consuming, and have high cost. To better simulate natural materials with micro/nanostructures that have evolved for millions of years, the use of ice templates has emerged as a promising method for producing biomimetic materials more efficiently. This article explores the historical approaches taken to produce traditional biomimetic structural biomaterials and delves into the principles underlying the ice-template method and their various applications in the creation of biomimetic materials. It also discusses the most recent biomedical uses of biomimetic materials created via ice templates, including porous microcarriers, tissue engineering scaffolds, and smart materials. Finally, the challenges and potential of current ice-template technology are analyzed.
{"title":"Fabricating biomimetic materials with ice-templating for biomedical applications.","authors":"Xiang Lin, Lu Fan, Li Wang, Anne M Filppula, Yunru Yu, Hongbo Zhang","doi":"10.1002/SMMD.20230017","DOIUrl":"10.1002/SMMD.20230017","url":null,"abstract":"<p><p>The proper organization of cells and tissues is essential for their functionalization in living organisms. To create materials that mimic natural structures, researchers have developed techniques such as patterning, templating, and printing. Although these techniques own several advantages, these processes still involve complexity, are time-consuming, and have high cost. To better simulate natural materials with micro/nanostructures that have evolved for millions of years, the use of ice templates has emerged as a promising method for producing biomimetic materials more efficiently. This article explores the historical approaches taken to produce traditional biomimetic structural biomaterials and delves into the principles underlying the ice-template method and their various applications in the creation of biomimetic materials. It also discusses the most recent biomedical uses of biomimetic materials created via ice templates, including porous microcarriers, tissue engineering scaffolds, and smart materials. Finally, the challenges and potential of current ice-template technology are analyzed.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230017"},"PeriodicalIF":0.0,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44967688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-26eCollection Date: 2023-08-01DOI: 10.1002/SMMD.20230012
Rawand A Mustafa, Petteri Parkkila, Jessica M Rosenholm, Hongbo Zhang, Tapani Viitala
In a healthcare setting, biofilms are a major source of infection and difficult to eradicate once formed. Nanoparticles (NPs) can be designed to effectively penetrate biofilms to more efficiently either deliver antibiotic drugs throughout the biofilm matrix or elicit inherent antibiofilm activity. Antibacterial cerium oxide (CeO2) NPs were employed as core material and coated with a mesoporous silica shell (MSN) to generate cerium oxide coated mesoporous silica NPs (CeO2@MSN). Detailed studies of NP-biofilm interactions are required to rationally develop NP platforms to prevent biofilm-related infections. This work developed and implemented a unique label-free analysis platform for the real-time monitoring of bacterial biofilm formation and then assessed the interactions of antibacterial NPs. An analysis platform which allows bacterial biofilms to grow and develop in situ in flow within the multi-parametric surface plasmon resonance (MP-SPR) instrument was established. This enabled simultaneous monitoring and detection of biofilm growth phases, structure, and interactions between differentially charged CeO2@MSNs and bacterial biofilms. Positively charged antibacterial NPs (polyethyleneimine functionalized CeO2@MSNs) were found to be the most efficient to penetrate the biofilm. The MP-SPR analysis platform was shown to be a powerful tool for monitoring biofilm development in real-time and to analyze biofilm properties and NP-biofilm interactions.
{"title":"Monitoring silica core@shell nanoparticle-bacterial film interactions using the multi-parametric surface plasmon resonance technique.","authors":"Rawand A Mustafa, Petteri Parkkila, Jessica M Rosenholm, Hongbo Zhang, Tapani Viitala","doi":"10.1002/SMMD.20230012","DOIUrl":"10.1002/SMMD.20230012","url":null,"abstract":"<p><p>In a healthcare setting, biofilms are a major source of infection and difficult to eradicate once formed. Nanoparticles (NPs) can be designed to effectively penetrate biofilms to more efficiently either deliver antibiotic drugs throughout the biofilm matrix or elicit inherent antibiofilm activity. Antibacterial cerium oxide (CeO<sub>2</sub>) NPs were employed as core material and coated with a mesoporous silica shell (MSN) to generate cerium oxide coated mesoporous silica NPs (CeO<sub>2</sub>@MSN). Detailed studies of NP-biofilm interactions are required to rationally develop NP platforms to prevent biofilm-related infections. This work developed and implemented a unique label-free analysis platform for the real-time monitoring of bacterial biofilm formation and then assessed the interactions of antibacterial NPs. An analysis platform which allows bacterial biofilms to grow and develop in situ in flow within the multi-parametric surface plasmon resonance (MP-SPR) instrument was established. This enabled simultaneous monitoring and detection of biofilm growth phases, structure, and interactions between differentially charged CeO<sub>2</sub>@MSNs and bacterial biofilms. Positively charged antibacterial NPs (polyethyleneimine functionalized CeO<sub>2</sub>@MSNs) were found to be the most efficient to penetrate the biofilm. The MP-SPR analysis platform was shown to be a powerful tool for monitoring biofilm development in real-time and to analyze biofilm properties and NP-biofilm interactions.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230012"},"PeriodicalIF":0.0,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49663174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-14eCollection Date: 2023-08-01DOI: 10.1002/SMMD.20230016
Danna Liang, Gaizhen Kuang, Xiang Chen, Jianhua Lu, Luoran Shang, Weijian Sun
Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S-nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near-infrared light (NIR)-responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor-killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR-responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR-responsive NO microcarriers are promising candidates in clinical tumor therapy applications.
{"title":"Near-infrared light-responsive Nitric oxide microcarrier for multimodal tumor therapy.","authors":"Danna Liang, Gaizhen Kuang, Xiang Chen, Jianhua Lu, Luoran Shang, Weijian Sun","doi":"10.1002/SMMD.20230016","DOIUrl":"10.1002/SMMD.20230016","url":null,"abstract":"<p><p>Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S-nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near-infrared light (NIR)-responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor-killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR-responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR-responsive NO microcarriers are promising candidates in clinical tumor therapy applications.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230016"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43384719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-02eCollection Date: 2023-08-01DOI: 10.1002/SMMD.20230008
Yuyan Chen, Zhengyi Zhu, Lu Zhang, Jinglin Wang, Haozhen Ren
Non-alcoholic fatty liver disease (NAFLD) is a typical chronic liver disease connected to a high risk of developing hepatocellular carcinoma (HCC). The development of NAFLD and HCC has been associated with changes in epigenetics, such as histone modifications and micro RNA (miRNA)-mediated processes. Recently, in the realm of epitranscriptomics, RNA alterations have become important regulators. N6-methyladenosine (m6A) is the most common and crucial alteration for controlling mRNA stability, splicing, and translation. It is particularly important for controlling liver disease progression and hepatic function. This review aims to conclude recent research on the functions of m6A epitranscriptome in the molecular mechanisms behind NAFLD and HCC development, with special attention to the effects of m6A alteration on how HCC develops and its possible roles in the progression of NAFLD to HCC. Additionally, the review discusses the possible effects of m6A alteration on the treatment and diagnostic of NAFLD and HCC. It is crucial to remember that m6A modification is a reversible action controlled via the coordinated functions of the proteins that write and delete, enabling quick adaptability to environmental changes. The review also discusses m6A-binding proteins' function in mRNA alternative splicing, translation, and degradation and their ability to modulate mRNA stability and processing. Understanding RNA modification regulation and its part in the emergence of HCC and NAFLD may provide new avenues for diagnosing and treating these diseases.
{"title":"Roles of N6-methyladenosine epitranscriptome in non-alcoholic fatty liver disease and hepatocellular carcinoma.","authors":"Yuyan Chen, Zhengyi Zhu, Lu Zhang, Jinglin Wang, Haozhen Ren","doi":"10.1002/SMMD.20230008","DOIUrl":"10.1002/SMMD.20230008","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is a typical chronic liver disease connected to a high risk of developing hepatocellular carcinoma (HCC). The development of NAFLD and HCC has been associated with changes in epigenetics, such as histone modifications and micro RNA (miRNA)-mediated processes. Recently, in the realm of epitranscriptomics, RNA alterations have become important regulators. N6-methyladenosine (m6A) is the most common and crucial alteration for controlling mRNA stability, splicing, and translation. It is particularly important for controlling liver disease progression and hepatic function. This review aims to conclude recent research on the functions of m6A epitranscriptome in the molecular mechanisms behind NAFLD and HCC development, with special attention to the effects of m6A alteration on how HCC develops and its possible roles in the progression of NAFLD to HCC. Additionally, the review discusses the possible effects of m6A alteration on the treatment and diagnostic of NAFLD and HCC. It is crucial to remember that m6A modification is a reversible action controlled via the coordinated functions of the proteins that write and delete, enabling quick adaptability to environmental changes. The review also discusses m6A-binding proteins' function in mRNA alternative splicing, translation, and degradation and their ability to modulate mRNA stability and processing. Understanding RNA modification regulation and its part in the emergence of HCC and NAFLD may provide new avenues for diagnosing and treating these diseases.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230008"},"PeriodicalIF":0.0,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45924842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-10eCollection Date: 2023-05-01DOI: 10.1002/SMMD.20230009
Tuomas Lasanen, Fanny Frejborg, Liisa M Lund, Marie C Nyman, Julius Orpana, Huda Habib, Salla Alaollitervo, Alesia A Levanova, Minna M Poranen, Veijo Hukkanen, Kiira Kalke
Herpes simplex virus type 1 (HSV-1) is a human pathogen that causes recurrent infections. Acyclovir-resistant strains exist and can cause severe complications, which are potentially untreatable with current therapies. We have developed siRNA swarms that target a 653 base pair long region of the essential HSV gene UL29. As per our previous results, the anti-UL29 siRNA swarm effectively inhibits the replication of circulating HSV strains and acyclovir-resistant HSV strains in vitro, while displaying a good safety profile. We investigated a single intranasal therapeutic dose of a siRNA swarm in mice, which were first inoculated intranasally with HSV-1 and given treatment 4 h later. We utilized a luciferase-expressing HSV-1 strain, which enabled daily follow-up of infection with in vivo imaging. Our results show that a single dose of a UL29-targeted siRNA swarm can inhibit the replication of HSV-1 in orofacial tissue, which was reflected in ex vivo HSV titers and HSV DNA copy numbers as well as by a decrease in a luciferase-derived signal. Furthermore, the treatment had a tendency to protect mice from severe clinical symptoms and delay the onset of the symptoms. These results support the development of antiviral siRNA swarms as a novel treatment for HSV-1 infections.
{"title":"Single therapeutic dose of an antiviral UL29 siRNA swarm diminishes symptoms and viral load of mice infected intranasally with HSV-1.","authors":"Tuomas Lasanen, Fanny Frejborg, Liisa M Lund, Marie C Nyman, Julius Orpana, Huda Habib, Salla Alaollitervo, Alesia A Levanova, Minna M Poranen, Veijo Hukkanen, Kiira Kalke","doi":"10.1002/SMMD.20230009","DOIUrl":"10.1002/SMMD.20230009","url":null,"abstract":"<p><p>Herpes simplex virus type 1 (HSV-1) is a human pathogen that causes recurrent infections. Acyclovir-resistant strains exist and can cause severe complications, which are potentially untreatable with current therapies. We have developed siRNA swarms that target a 653 base pair long region of the essential HSV gene <i>UL29</i>. As per our previous results, the anti-UL29 siRNA swarm effectively inhibits the replication of circulating HSV strains and acyclovir-resistant HSV strains in vitro, while displaying a good safety profile. We investigated a single intranasal therapeutic dose of a siRNA swarm in mice, which were first inoculated intranasally with HSV-1 and given treatment 4 h later. We utilized a luciferase-expressing HSV-1 strain, which enabled daily follow-up of infection with in vivo imaging. Our results show that a single dose of a UL29-targeted siRNA swarm can inhibit the replication of HSV-1 in orofacial tissue, which was reflected in ex vivo HSV titers and HSV DNA copy numbers as well as by a decrease in a luciferase-derived signal. Furthermore, the treatment had a tendency to protect mice from severe clinical symptoms and delay the onset of the symptoms. These results support the development of antiviral siRNA swarms as a novel treatment for HSV-1 infections.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20230009"},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41580158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuomas Lasanen, Fanny Frejborg, Liisa M. Lund, Marie C. Nyman, Julius Orpana, Huda Habib, Salla Alaollitervo, Alesia A. Levanova, M. Poranen, V. Hukkanen, Kiira Kalke
{"title":"Single therapeutic dose of an antiviral UL29 siRNA swarm diminishes symptoms and viral load of mice infected intranasally with HSV‐1 (2/2023)","authors":"Tuomas Lasanen, Fanny Frejborg, Liisa M. Lund, Marie C. Nyman, Julius Orpana, Huda Habib, Salla Alaollitervo, Alesia A. Levanova, M. Poranen, V. Hukkanen, Kiira Kalke","doi":"10.1002/smmd.65","DOIUrl":"https://doi.org/10.1002/smmd.65","url":null,"abstract":"","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45780591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Issue Information","authors":"","doi":"10.1111/raju.12348","DOIUrl":"https://doi.org/10.1111/raju.12348","url":null,"abstract":"No abstract is available for this article.","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41682422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}